Mesenterointestinocolonovascular arterial ischemic disease
Guidelines of the Angiology section of Slovak Medical Chamber (AS SMC, 2013)

1. Anderson JL, Halperin JL, Albert NM et al. Management of Patients With Peripheral Artery Disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(13): 1425–1443.

2. Hirsh AT, Haskal ZJ, Hertzer ZJ et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47(6): 1239–1312.

3. Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58(19): 2020–2045.

4. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(22): 2851–2906.

5. TASC. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol 2000; 19(Suppl 1): 1–304.

6. Norgren L, Hiatt WR, Dormandy JA et allf of (the TASC II Working Group). Inter-society consensus for the management of peripheral arterial disease. Int angiol 2007; 26(2): 81–157.

7. Van den Heijkant TC, Aerts BAC, Teijink JA et al. Challenges in diagnosing mesenteric ischemia. World J Gastroenterol 2013; 19(9): 1338–1341.

8. Zacho HD, Henriksen JH, Abrahamsen J. Chronic intestinal ischemia and splanchnic blood-flow: Reference values and correlation with body-composition. World J Gastroenterol 2013; 19(6): 882–888.

9. Saba L, Berritto D, Iacobellis F et al. Acute arterial mesenteric ischemia and reperfusion: macroscopic and MRI findings, preliminary report. World J Gastroenterol 2013; 19(40): 6825–6833.

10. Keese M, Schmitz-Rixen T, Schmandra T. Chronic mesenteric ischemia: time to remember open revascularization. World J Gastroenterol 2013; 19(9): 1333–1337.

11. World Gastroenterology Organisation (WGO). Practice Guideline: Malabsorption. Dostupné z WWW: <http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/13_malabsorption_en.pdf. 6.11.2013>.

12. Cangemi JR, Picco JF. Intestinal ischemia in the elderly. Gastroenterol Clin North Am 2009; 38(3): 527–540.

13. Gonenc M, Dural CA, Kocatas A et al. The impact of early diagnostic laparoscopy on the prognosis of patients with suspected acute mesenteric ischemia. Eur J Trauma Emerg Surgery 2013; 39(2): 185–189.

14. Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology 2000; 118(5): 954–968.

15. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949–3003.

16. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2281–2329..

17. Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heatrt J 2013; 34(39): 3035–3087.

18. Gavorník P. Končatinovocievne ischemické choroby. B 2.1/1–92. In: Gavorník P, Hrubiško M, Rozborilová E (eds). Diferenciálna diagnostika kardio-vaskulárnych, respiračných a hematologických ochorení. I. Dr. Josef Raabe: Bratislava 2010, 300 s. ISBN 978–80–89182–46–6.

19. Gavorník P. Obliterujúce choroby artérií a končatinovocievna ischemická choroba. Nová klinicko-etiologicko-anatomicko-patofyziologická klasifikácia. Kardiológia/Cardit?ology 2010; 19(3): 201–213.

20. Gavorník P. Etiopatogenéza neurovaskulárnych ischemických chorôb (syndrómov). Neurológia 2010; 5(2): 61–68.

21. Gavorník P. Cielené vysvetľovanie cievnych chorôb a cievnych porúch. „Srdcovocievne choroby“, „srdcovo-cievne choroby“, „srdcovocievny systém“, srdcovo-cievny systém“, „srdcovo-cievne abnormality“, „srdcovocievne poruchy“, „kardiovaskulárne choroby“, „kardiovaskulárna medicína“ – počujeme a čítame to denne. Vieme, o čo ide? Kardiológia/Cardiology letters 2009; 18(5): 84–85.

22. Gavorník P. Cielené vysvetľovanie cievnych chorôb a cievnych porúch. Vnitr Lek 2009; 55(10): 996–997.

23. Gavorník P, Galbavý Š. Clinical picture of arteriolosclerosis. Bratislavské lek listy 2001; 102(7): 326–331.

24. Gavorník P, Gavorník P. Očný ischemický syndróm a iné vaskulárne choroby oka. Univerzita Komenského – Vydavateľstvo UK: Bratislava 2008. ISBN 978–80–223–2473–1.

25. Gavorník P. Angiológia. Univerzita Komenského – Vydavateľstvo UK: Bratislava 1998. ISBN 80–223–1218–5

26. Gavorník P. Ateroskleróza a iné choroby tepien. Univerzita Komenského -Vydavateľstvo UK: Bratislava 1999. ISBN 80–223–1422–6. 27. Gavorník P. Diabetic angiopathy – etiopathogenesis and clinical manifestations (hypersyndrome X). Bratislavské lek listy 2000; 101(10): 569–676.

28. Gavorník P. Vaskulárna endotelová dysfunkcia – etiopatogenéza, základné diagnostické metódy a liečebné možnosti. Gen Angiol 2002; 2(2): 59–66.

29. Gavorník P. Cievne choroby. In: Klimo F et al. Praktické a rodinné lekárstvo. Prognóza: Senica 1999: 382–400. ISBN 80–968295–4-8.

30. Gavorník P. Choroby tepien. In: Ďuriš I, Hulín I, Bernadič M (eds.: Princípy internej medicíny I-III. Slovac Academic Press: Bratislava 2001: 784–797. ISBN 80–88908–69–8.

31. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. Univerzita Komenského – Vydavateľstvo UK: Bratislava 2001. 2nd ed. ISBN 80–223–1608–3. 268 s.

32. Ip JH, Fuster V, Badimon L et al. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Amer Coll Cardiol 1990; 15(7): 1667–1687.

33. Kappert A. Angiológia. choroby tepien, žíl, vlásočníc a lymfatických ciev. Učebnica a atlas. Osveta: Martin 1987. 488 s.

34. Karetová D, Staněk F (eds.). Angiologie pro praxi. Maxdorf: Praha 2001. ISBN 80–85912–52-X. 196 s.

35. Prusík B, Reiniš Z et al. Nemoci končetinových cév v klinické praxi. Státní zdravotnické nakladatelství: Praha 1959. 488 s.

36. Puchmayer V, Roztočil K. Praktická angiologie. Triton: Praha 2000, ISBN 80–7254- 099–8. 192 s.

37. Stary HC, Chandler AB, Glagov S et al. Definition of initial, fatty streak and intermediate lesions of atherosclerosis. A report from Commitee on vascular lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89(5): 2462–2478.

38. Smith jr SC, Benjamin EJ, Bonow RO et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011; 58(23): 2432–2446.

39. Peach GG, Griffin M, Jones KG et al. Diagnosis and management of peripheral arterial disease. BMJ 2012; 345: e5208. 345: 36–41.

40. Alhadad A, Wictorsson C, Alhadad H et al. Medical risk factor treatment in peripheral arterial disease. Need for further improvement. Int angiol 2013; 32(3): 332–338.

41. Jurgoš Ľ, Kužela L, Hrušovský Š et al. Gastroenterológia. Veda: Bratislava 2006. ISBN 80–224–0893-X. 688 s.

42. Gavorník P. Ateroskleróza a iné choroby tepien. Univerzita Komenského -Vydavateľstvo UK: Bratislava 1999. ISBN 80–223–1422–6. 216 s.

43. Gavorník P. Efektívna racionálna prevencia a liečba orgánovocievnych artériových ischemických chorôb v preventívnej vaskulárnej medicíne. I-med 2012; 2: 1–30. doi http://www.i-med.sk/internistické disciplíny/angiológia.

44. Gavorník P, Gašpar Ľ, Dukát A. Manažment angioedému. Odporúčania Angiologickej sekcie Slovenskej lekárskej komory (2013). Vnitř Lék 2013; v tisku.

45. Gavorník P. Prevencia a liečba orgánovovaskulárnych artériových chorôb. In: Kiňová S, Hulín I et al. Interná medicína. Prolitera: Bratislava 2013. 391–393. ISBN 978–80–970253–9-7. 1136 s.

46. Gavorník P. Orgánovovaskulárne artériové ischemické choroby, ateroskleróza a iné artériové choroby. 1. časť: Ateroskleróza. I-med 2012; 2: 1–24. Prístupné na http://www.i-med.sk/internistické disciplíny/angiológia. ISSN 1338–4392.

47. Gavorník P. Orgánovovaskulárne artériové ischemické choroby, ateroskleróza a iné artériové choroby. 2. časť: Nonaterosklerotické artériové choroby. I-med 2012; 2: 1–133. Prístupné na http://www.i-med.sk/internistické disciplíny/angiológia. ISSN 1338–4392.

48. Gavorník P. Vaskulárna endotelová dysfunkcia – etiopatogenéza, základné diagnostické metódy a liečebné možnosti. Gen Angiol 2002; 2(2): 59–66.

49. Atkinson G, Batterham AM, Thijssen DHJ et al. A new approach to improve the specificity of flow-mediated dilation for indicating endothelial function in cardiovascular research. J Hypertens 2013; 31(2): 287–291.

50. Ricco JB, Naylor AR, Gough MJ et al. Management of critical limb ischaemia and diabetic foot. Clinical practice guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg 2011; 42: (Suppl 2): S1-S90.

51. Smolderen KG, Wang K, de Pouvourville G et al. REACH Registry Investigators. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherosclerosis in France and Germany. Highest burden for peripheral arterial disease. Eur J Vasc Endovasc Surg 2012; 43(2): 198–207.

52. Wisman PP, Tangelder MJ van Hattum ES et al. Young women with PAD are at high risk of cardiovascular complications. Eur J Vasc Endovasc Surg 2012; 43(4): 441–445.

53. Van de Luijitgaarden KM, Voûte MT, Hoeks SE et al. Vitamin D deficiency may be an independent risk factors for arterial disease. Eur J Vasc Endovasc Surg 2012; 44(3): 301–306.

54. Brownrigg JRW, Apelquist J, Bakker K et al. Evidence-based management of PAD and the diabetic foot. Eur J Vasc Endovasc Surg 2013; 45(6): 673–681.

55. Schwarcz AI, Quijano A, Olin JW et al. Internal medicine interns have a poor knowledge of peripheral arterial disease. Angiology 2012; 63(8): 597–602.

56. Rabkin SW, Chan SH, Sweeney C. Ankle-brachial index as an indicator of arterial stiffness in patients without peripheral arterial disease. Angiology 2012; 63(2): 150–154.

57. Khurana A, Stoner JA, Whitsett TL et al. Clinical Significance of Ankle Systolic Blood Pressure Following Exercise in Assessing Calf Muscle Tissue Ischemia in Peripheral Artery Disease. Angiology 2013; 64(5): 364–370.

58. Van Diepen JA, Berbée JF, Havekes LM et al. Interactions between inflammation and lipid metabolism: Relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 2013; 228(2): 306–315.

59. Cronin O, Morris DR, Walker PJ et al. The association of obesity with cardiovascular events in patients with peripheral arterial disease. Atherosclerosis 2013; 228(2): 316–323.

60. Marsico F, Rugiero D, Parente A et al. Prevalence and severity of asymptomatic coronary and carotid artery disease in patients with lower limb arterial disease. Atherosclerosis 2013; 228(2): 386–389.

61. Arcidiacono MV, Traveset A, Rubinat E et al. Microangiopathy of large artery wall: neglected complication of diabetes mellitus. Atherosclerosis 2013; 228(1): 142–147.

62. Williams PT, Thompson PD. Walking versus Running for Hypertension, Cholesterol, and Diabetes mellitus Risk Reduction. Arterioscler Thromb Vasc Biol 2013; 33(5): 1085–1091.

63. Bertoia ML, Pai JK, Lee JH et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol 2013; 61(21): 2169–2179.

64. Jain A, Liu K, Ferrucci L et al. Declining walking impairment questionnaire scores are associated with subsequent increased mortality in peripheral artery disease. J Am Coll Cardiol 2013; 61(17): 1820–1829.

65. Savji N, Rockman CB, Skolnick AH et al. Association between advanced age and vascular disease in different arterial territories. a population database of over 3.6 million subjects. J Am Coll Cardiol 2013; 61: 1736–1743.

66. Jackson R, Kerr A, Wells S. Vascular risk calculators: essential but flawed clinical tools? Circulation 2013; 127(19): 1929–1931.

67. Allan GM, Nouri F, Korownyk C et al. Agreement among cardiovascular disease risk calculators. Circulation 2013; 127(19): 1948–1956.

68. Gavorník P, Dukát A, Gašpar Ľ. Manažment stabilnej anginy pectoris a iných foriem chronickej kardiovaskulárnej artériovej choroby. Vnitř Lék 2012; 58(7 a 8): 29–36. 58: CD29-CD36.

69. Gavorník P, Dukát A, Gašpar Ľ et al. Endotelová dysfunkcia a multiorgánovomultivaskulárna (polyorgánovopolyvaskulárna) choroba. Forum Diab 2012; 1(2–3): 77–85. Forum diabetologicum 2012; 1(2–3): 77–85.

70. Perk J, De Backer G, Gohlke H et al. Joint ESC Guidelines. European Guidelines on cardiovascular disease prevention in clinical practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33(13): 1635–1701.

71. Gavorník P, Dukát A, Gašpar Ľ et al. Odporúčania Sekcie angiológov SLK pre manažment artériovej hypertenzie (2011). Cievy – páchateľky, nástroje i obete artériovej hypertenzie (cievnej choroby cievnych chorôb). Ateroskleróza 2011; 15(1–2): 79–84.

72. Gavorník P. Artériová hypertenzia: Cievy – páchateľky, nástroje i obete artériovej hypertenzie. Odporúčania podľa Sekcie angiológov SLK pre manažment artériovej hypertenzie. I-med 2012; 2: 1–38. Prístupné na http://www. i-med.sk/internistické disciplíny/angiológia. ISSN 1338–4392.

73. Garcia-Malpartida K, Marmol R, Jover A et al. Relationship between erectile dysfunction and silent myocardial ischemia in type 2 diabetic patients with no known macrovascular complications. J Sex Med 2012; 8(9): 2606–2016.

74. Garcia-Ortiz L, Ramos-Delgado E, Recio-Rodriguez JI et al. Peripheral and central arterial pressure and its relationship to vascular target organ damage in carotid artery, retina and arterial stiffness. Development and validation of a tool. The Vaso risk study. BMC Publ Health 2011; 11: 266.

75. Hernandez-Mijares A, Garcia-Malpartida K, Sola-Izquierdo E et al. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010; 7(5): 1954–1964.

76. Cardoso CR, Ferreira MT, Leite NC et al. Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atherosclerosis 2009; 205(2): 472–476.

77. Armario P, Oliveras A, Hernandez Del Rey R et al. Prevalence of target organ damage and factors associated with cardiovascular events in subjects with refractory hypertension. Med Clin (Barc) 2009; 133(4): 127–131.

78. Widimský jr. J. Variabilita krevního tlaku a arteriální hypertenze. Vnitř Lék 2011; 57(3): 320–324.

79. Dukát A, Mikeš Z, Kolesár J et al. Možnosti klinického použitia ambulantného monitorovania krvného tlaku. Čas Lék Čes 1988; 127(2): 46–51.

80. Dukát A, Gavorník P, Lietava J et al. Ambulatory ECG, BP and peripheral resistance monitoring during silent ischaemia episodes among hypertensives. Ateroskleróza 1997; 1(2): 56.

81. Sowers JR. Diabetes mellitus and vascular disease. Hypertension 2013; 61(5): 943–947.

82. Rumsfeld JS, Alexander KP, Goff DC et al. on behalf of the American Heart Association Council on Quality of Care and Outcomes Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, and Stroke Council. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation 2013; 127(22): 2233–2249.

83. Estruch R, Ros E, Sulas-Salvádo J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368(14): 1279–1290.

84. Hodgkinson JA, Sheppard JP, Heneghan C et al. Accuracy of ambulatory blood pressure monitors: a systemic review of validation studies. J Hypertens 2013; 31(2): 239–250.

85. Brook RD, Appel LJ, Rubenfire M et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension 2013; 61: 1360–1383.

86. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013; 61(5): 964–971.

87. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382(9889):339–352. doi:10.1016/S0140–6736(13)60595–4.

88. Zanchetti A. Ambulatory blood pressure monitoring, arterial function and other problems concerning hypertension. J Hypertens 2013; 31(9): 1729–1730.

89. O’Brien E, Parati G, Stergiou G et al. European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. J Hypertens 2013; 31(9): 1731–1768.

90. Westerhof N, Westerhof BE. A review of methods to determine the functional arterial parameters stiffness and resistance. J Hypertens 2013; 31(9): 1769–1775.

91. Hafner J, Nobbe S, Läuchli S et al. Martorell hypertensive ischemic leg ulcer (HYTILU) must not be confounded with pyoderma gangrenosum: Management is totally different. Rev Vasc Med 2013; 1(1): 5–8.

92. Uhlig K, Patel K, Ip S et al. Self-Measured Blood Pressure Monitoring in the Management of Hypertension: A Systematic Review and Meta-analysis. Ann Intern Med 2013; 159(3): 185–194. doi:10.7326/0003–4819–159–3-201308060–00008.

93. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Daniels SR, Benuck I, Christakis DA et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Pediatrics 2011; 128: (Suppl 5): S213-S256.

94. Gavorník P, Dukát A, Gašpar Ľ. Manažment dyslipidémií – prítomnosť a budúcnosť. Odporúčania Sekcie angiológov Slovenskej lekárskej komory (2013). Vnitř Lék 2013; 59(10): 932–938.

95. Gavorník P, Dukát A., Gašpar Ľ. Súčasnosť a budúcnosť farmako-artériotromboprofylaxie v klinickej praxi. Dokument (Odporúčania) Sekcie angiológov Slovenskej lekárskej komory. (SA SLK, 2013). Vnitr Lek 2013; 59(12): 1081–1087.

96. Gavorník P, Gašpar Ľ, Dukát A. Kombinovaná kinezio-flebotromboemboloprofylaxia, mechano-flebotromboemboloprofylaxia a farmako-flebotromboemboloprofylaxia vénovej tromboembólie v internej medicíne. Odporúčania Sekcie angiológov Slovenskej lekárskej komory (SA SLK). Vnitř Lék 2012; 58(11): 851–855.

97. Guyatt GH, Akl EA, Crowther M et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines. Chest 2012; 141: (Suppl 2): 48S-52S. e1S-e801S.

98. Páral J. Akutní mezenteriální ischemie. Moderní diagnostika a léčba akutní ischemie střeva. Praha: Grada 2012. ISBN 978–80–247–3996–0.